Paul Goodfellow, MS, PhDOhio State University Role of BRIP1 helicase missense mutations in ovarian cancer BRIP1 gene has recently been recognized as an ovarian cancer susceptibility gene, based primarily on discovery of mutations that result in a truncated, or shortened, BRIP1 protein that no longer functions properly. Most genetic variation in the BRIP1 gene, however, […]
Read More
Andrea Facciabene, PhDUniversity of Pennsylvania Tumor development influences gut flora – possible implication in early detection Early detection of ovarian cancer represents the best hope for mortality reduction and long-term disease control. Dr. Facciabene’s preliminary data indicate that developing ovarian cancer induces change in the microorganisms found in the gut, also known as the gut […]
Read More
Simon Chu, PhDMonash University PPARgamma Activation Augments Anticancer Effects of XIAP Inhibition in Ovarian Granulosa Cell Tumors Granulosa cell tumors of the ovary arise due to dysfunction of the granulosa cells, which are support cells in the ovary, involved in ovulation and production of hormones. Dr. Chu will determine if using therapeutic drugs that act […]
Read More
Ilana Chefetz, PhDUniversity of Minnesota, Twin Cities Deciphering molecular mechanism of ALDH-inhibition driven necroptosis Dr. Chefetz-Menaker recently demonstrated that chemotherapy resistant ovarian cancer stem-like cells (CSC) can be identified by a protein activity known as ALDH. The expression of ALDH in CSC allows a unique opportunity to develop therapeutics specifically targeting CSC, which are thought […]
Read More
Karen Belkic, MD, PhDKarolinska Institute Optimized Magnetic Resonance Spectroscopy for Early Ovarian Cancer Detection When diagnosed early, ovarian cancer has an excellent prognosis, but current imaging methods for detecting ovarian cancer have not yet yielded the hoped-for benefit. Standard clinical magnetic resonance scanners produce images of poor quality, with low resolution and limited information content. […]
Read More
Fiona Yull, D.Phil.Vanderbilt University Bromodomain inhibition in ovarian cancer and the tumor microenvironment Scientists are actively working to find new therapies for ovarian cancer as resistance to current therapies, including PARP inhibitors and cisplatin, poses a major problem in the clinic. One promising approach is to develop strategies that activate the patient’s normal immune system […]
Read More
Yunfei Wen, PhDUniversity of Texas MD Anderson Cancer Center Overcoming acquired resistance to antiangiogenic therapy by targeting vascular p130cas Angiogenesis, the process of forming a new network of blood vessels from existing ones, is a central hallmark of cancer. In order for a tumor to grow, it must have the blood flow necessary to feed […]
Read More
Carlos Telleria, PhDMcGill University Health Center Proteotoxic Stress Therapy in Ovarian Cancer The majority of ovarian cancers recur 18-24 months after first responding to chemotherapy. Residual cells hide out in the abdominal cavity and often become unresponsive to current chemotherapy when they grow back. Dr. Telleria researches therapies that would be administered chronically after chemotherapy […]
Read More
Fiona Simpkins, MDUniversity of Pennsylvania School of Medicine Circumventing drug resistance mechanisms in CCNE1 amplified ovarian cancers More than 80% of patients with high-grade serous ovarian cancer (HGSOC) develop resistance to treatment and eventually succumb to their disease. The need to develop new treatments for this form of ovarian cancer is dire. About 65% of […]
Read More
Rosana Risques, PhDUniversity of Washington 2017 Pape Family Pilot Study Award Characterization of TP53 mutations in BRCA carcinogenesis Women with inherited mutations in the BRCA1 and BRCA2 genes have a greatly increased risk of developing high-grade serous ovarian cancer (HGSOC). This type of cancer starts as a lesion in the fallopian tube, and these lesions almost always contain cells […]
Read MoreStarting April 1, 2025, the Rivkin Center’s ovarian cancer research funding, global symposium and fundraising activities will continue under the leadership of Ovarian Cancer Research Alliance (OCRA).
